Rheumatologic association center of Iran Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2009
NCT01873625
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

President of rheumatologic association center of Iran

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Osteoarthritis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1